Literature DB >> 17618235

Multidrug-resistant Providencia isolates carrying blaPER-1, blaVIM-2, and armA.

Hee-Woo Lee1, Hee-Young Kang, Kyeong-Seob Shin, Jungmin Kim.   

Abstract

During May to July 2004, three strains of Providencia spp. with multidrug-resistance (MDR) were isolated from urinary specimen of three patients hospitalized with a same hospital room. By PCR analysis, all three strains have been found to carry both VIM-2 type metallo-beta-lactamase gene and PER-1 type extendedspectrum beta-lactamase gene. One out of three strains carried additional resistance gene, armA, 16S rRNA methylase gene responsible for high level resistance to aminoglycosides. To our knowledge, this is the first report on the identification of Providencia spp. simultaneously carrying blaVIM-2, blaPER-1, and armA genes.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17618235

Source DB:  PubMed          Journal:  J Microbiol        ISSN： 1225-8873            Impact factor:   3.422


  17 in total

1.  Detection and characterization of VIM-31, a new variant of VIM-2 with Tyr224His and His252Arg mutations, in a clinical isolate of Enterobacter cloacae.

Authors:  Pierre Bogaerts; Carine Bebrone; Te-Din Huang; Warda Bouchahrouf; Yves Degheldre; Ariane Deplano; Kurt Hoffmann; Youri Glupczynski
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

2.  A Tailspike with Exopolysaccharide Depolymerase Activity from a New Providencia stuartii Phage Makes Multidrug-Resistant Bacteria Susceptible to Serum-Mediated Killing.

Authors:  Hugo Oliveira; Graça Pinto; Bruna Mendes; Oscar Dias; Hanne Hendrix; Ergun Akturk; Jean-Paul Noben; Jan Gawor; Małgorzata Łobocka; Rob Lavigne; Joana Azeredo
Journal:  Appl Environ Microbiol       Date:  2020-06-17       Impact factor: 4.792

3.  Emergence of extended-spectrum beta-lactamase PER-1 in Proteus vulgaris and Providencia stuartii isolates from Algiers, Algeria.

Authors:  Hassen Iabadene; Caroline Dallenne; Yamina Messai; Delphine Geneste; Rabah Bakour; Guillaume Arlet
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

4.  PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.

Authors:  Delphine Girlich; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

5.  Providencia isolates carrying bla (PER-1) and bla (VIM-2) genes: biofilm-forming capacity and biofilm inhibitory concentrations for carbapenem antibiotics.

Authors:  Jungmin Kim; Shukho Kim; Hee Woo Lee; Sung Min Kim; Sung Yong Seol
Journal:  J Microbiol       Date:  2011-06-30       Impact factor: 3.422

6.  Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives.

Authors:  Sylvie Garneau-Tsodikova; Kristin J Labby
Journal:  Medchemcomm       Date:  2015-09-21       Impact factor: 3.597

7.  Diversity of clavulanic acid-inhibited extended-spectrum β-lactamases in Aeromonas spp. from the Seine River, Paris, France.

Authors:  Delphine Girlich; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2010-12-13       Impact factor: 5.191

8.  Emergence of Carbapenem-Resistant Providencia rettgeri and Providencia stuartii Producing IMP-Type Metallo-β-Lactamase in Japan.

Authors:  Shu Iwata; Tatsuya Tada; Tomomi Hishinuma; Mari Tohya; Satoshi Oshiro; Kyoko Kuwahara-Arai; Miho Ogawa; Masahiro Shimojima; Teruo Kirikae
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

9.  Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment.

Authors:  Michael B Burns; Joshua Lynch; Timothy K Starr; Dan Knights; Ran Blekhman
Journal:  Genome Med       Date:  2015-06-24       Impact factor: 11.117

10.  NDM-1 Metallo-β-Lactamase and ArmA 16S rRNA methylase producing Providencia rettgeri clinical isolates in Nepal.

Authors:  Tatsuya Tada; Tohru Miyoshi-Akiyama; Rajan K Dahal; Manoj K Sah; Hiroshi Ohara; Kayo Shimada; Teruo Kirikae; Bharat M Pokhrel
Journal:  BMC Infect Dis       Date:  2014-02-03       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.